Gaboxadol. Lundbeck/Merck
Huckle, R.
Current Opinion in Investigational Drugs 5(7): 766-773
2004
ISSN/ISBN: 1472-4472 PMID: 15298075 Document Number: 580460
H Lundbeck A/S, in collaboration with Merck & Co Inc, is developing gaboxadol, a GABAA agonist, for the potential treatment of sleep disorders. The compound is currently undergoing phase III clinical trials.